Is There a Place for Immunotherapy with Interleukin-2 to Prevent Relapse after Autologous Stem Cell Transplantation for Acute Leukemia?

References

• Gale R.P., Champlin R.E. How does bone marrow transplantation cure leukaemia?. Lancet 1984; 2: 28–30
   PubMed Web of Science ®Google Scholar
• Fefer A., Sullivan K.M., Weiden P. Graft-versus-leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 1987; 244: 401–408
   PubMedGoogle Scholar
• Phillips G.L., Reece D.E., Shepherd J.D., Barnett M.J., Brown R.A., Frei-Lahr D.A., Klingemann H-G., Boswell B.J., Spinelli J.J., Herzig R.H., Herzig G.P. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 11: 1429–1435
   Google Scholar
• Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 1979; 300: 1068–1073
   PubMed Web of Science ®Google Scholar
• Sullivan K.M., Weiden P.L., Storb R., Witherspoon R.P., Fefer A., Fisher L., Buckner C.D., Anasetti C., Appelbaum F.R., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow C., Cheever M.A., Clift R., Deeg H.J., Doney K., Greenberg P., Hansen J.A., Hill R., Loughran T., Martin P., Neiman P., Petersen F.B., Sanders J., Singer J., Stewart P., Thomas E.D. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989; 73: 1720–1728
   PubMed Web of Science ®Google Scholar
• Verdonck L.F., ban Heugten H.G., Giltay J., Franks C.R. Amplification of the graft-versus-leukemia effect in man by interleukin-2. Transplantation 1991; 51: 1120–1123
   PubMed Web of Science ®Google Scholar
• Klingemann H-G., Phillips G.L. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant. 1991; 8: 73–81
   PubMed Web of Science ®Google Scholar
• Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H-J., Rimm A.A., Ringden O., Rozman C., Speck B., Truitt R.L., Zwaan F.E., Bortin M.M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Champlin R., Gale R.P. Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 1989; 73: 2051–2066
   PubMed Web of Science ®Google Scholar
• Kersey J.H., Weisdorf D., Nesbit M.E., LeBien T.W., Woods W.G., McGlave P.B., Kim T., Vallera D.A., Goldman A.I., Bostrom B., Hurd D., Ramsay N.K.C. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 1987; 317: 461–467
   PubMed Web of Science ®Google Scholar
• Simonsson B., Burnett A.K., Prentice H.G., Hann I.H., Brenner M.K., Gibson B., Grob J.P., Lonnerholm G., Morrison A., Smedmyr B., Todd A., Oberg G., Gilmore M., Campana D., Totterman T. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 3: 631–636
   PubMed Web of Science ®Google Scholar
• Uckun F., Kersey J.H., Vallera D.A., Ledbetter J.A., Weisdorf D., Myers D.E., Haake R., Ramsay N.K.C. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxy-cyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Brenner M.K., Rill D.R., Moen R.C., Krance R.A., Mirro J., Jr., Anderson W.F., Ihle J.N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Clift R.A., Buckner C.D., Appelbaum F.R., Bearman S.I., Petersen F.B., Fisher L.D., Anasetti C., Beatty P., Bensinger W.I., Doney K., Hill R.S., McDonald G.B., Martin P., Sanders J., Singer J., Stewart P., Sullivan K.M., Witherspoon R., Storb R., Hansen J.A., Thomas E.D. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871
   PubMed Web of Science ®Google Scholar
• Forman S.J., Wright C.L., Scanlon K., Doroshow J. Sensitivity of chemo-resistant leukemia cells to IL-2 activated killer cells. Blood 1989; 74: 118a, Suppl. 1
   Google Scholar
• Gorin N.C., Labopin M., Meloni G., Korbling M., Carella A., Herve P., Burnett A., Rizzoli V., Alessandrino E.P., Bjorkstrand B., Fen-Ant A., Lowenberg B., Coser P., Simonsson B., Helbig W., Brunet Mauri S., Verdonck L.F., Iriondo A., Polli E., Colombat P., Franklin I.M., Souillet G., Willemze R. Autologous bone marrow transplantation for acute myeloblasts leukemia in Europe: Further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896–904
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens P., Brandely M., Olive D., Lopez M., Sainty D., Marit G., Stoppa A.M., Reiffers J., Gratecos N., Bertau-Perez P., Mannoni P., Mawas C., Hercend T., Sebahoun G., Carcassonne Y. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182–2187
   PubMed Web of Science ®Google Scholar
• Heslop H.E., Gottlieb D.J., Bianchi A.C.M., Meager A., Prentice H.G., Mehta A.B., Hoffbrand A.V., Brenner M.K. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Grabstein K.H., Urdal D.L., Tushinski R.J., Mochizuki D.Y., Price B.L., Cantrell M.A., Gillis S., Conlon P.J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232: 506–508
   PubMed Web of Science ®Google Scholar
• Wei S., Blanchard D.K., Liu J.H., Leonard W.J., Djeu J.Y. Activation of tumor necrosis factor-a production from human neutrophils by IL-2 via IL-2-RR. J. Immunol. 1993; 150: 1979–1987
   PubMed Web of Science ®Google Scholar
• Fierro M.T., Liao X-S., Lusso P., Bonferroni M., Matera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lym-phokine activated killer activity. Leukemia 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M.T., Cesano A., Guarini A., Bonferroni M., Raspadori D., Miniero R., Lauria F., Gavosto F. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 1991; 78: 1041–1046
   PubMed Web of Science ®Google Scholar
• Panayotides P., Porwit A., Sydgren AM., Wasserman J., Reizenstein P. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells. Eur. J. Haematol. 1988; 40: 362–367
   PubMed Web of Science ®Google Scholar
• Klingemann H-G., Gong H-J., Maki G., Horsmanaa D.E., Dalai B.I., Phillips G.L. Establishment and characterization of a human leukemic cell line (SR-91) with features suggestive of early hematopoietic progenitor cell origin. Leak. Lymphoma 1994; 12: 463–470
   PubMed Web of Science ®Google Scholar
• Schirren C.A., Volpel H., Meuer S.C. Adhesion molecules on freshly recovered T leukemias promote tumor-directed lympholysis. Blood 1992; 19: 138–143
   Google Scholar
• Chen W., Peace D.J., Rovira D.K., You S-G., Cheever M.A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA 1992; 89: 1468–1472
   PubMed Web of Science ®Google Scholar
• Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465
   PubMed Web of Science ®Google Scholar
• Drobyski W.R., Keever C.A., Roth M.S., Koethe S., Hanson G., McFadden P., Gottschall J.L., Ash R.C., ban Tuinen P., Horowitz M.M., Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318
   PubMed Web of Science ®Google Scholar
• Kolb H.J., deWitte T., Mittermuller J., Hertenstein B., Goldman J.M., Liungman P., Verdonck L., Holler E., Thalmaier K., Bartram C. Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation. Blood 1993; 82: 214a
   Web of Science ®Google Scholar
• Szer J., Grigg A.P., Phillips G.L., Sheridan W.P. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant. 1993; 11: 109–111
   PubMed Web of Science ®Google Scholar
• Veda M., Joshi I.D., Dan M., Uberti J.P., Chou T-H., Sensenbrenner L.L., Lum L.G. Preclinical studies for adoptive immunotherapy in bone marrow transplantation: Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993; 56: 351–356
   PubMed Web of Science ®Google Scholar
• Anderson P.M., Ochoa A.C., Ramsay N.K.C., Hasz D., Weisdorf D. Anti-CD3+interleukin-2 stimulation of marrow and blood: Comparison of proliferation and cytotoxicity. Blood 1992; 80: 1846–1853
   PubMed Web of Science ®Google Scholar
• Reittie J.E., Gottlieb D., Heslop H.E., Leger O., Drexler H.G., Hazlehurst G., Hoffbrand A.V., Prentice H.G., Brenner M.K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Niederwieser D., Gasti G., Ruampold H., Marth C., Kraft D., Huber C. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (N K) activity after human bone marrow transplantation (BMT). Br. J. Haematol 1987; 65: 301–305
   PubMed Web of Science ®Google Scholar
• Welte K., Ciobanu N., Moore M.A., Gulati S., O'Reilly R.J., Mertelsmann R. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood 1984; 64: 380–385
   PubMed Web of Science ®Google Scholar
• Higuchi C.M., Thompson J.A., Cox T., Lindgren C.G., Buckner C.D., Fefer A. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res. 1989; 49: 5509–5513
   PubMed Web of Science ®Google Scholar
• Mori T., Tsoi M-S., Gillis S., Santos E., Thomas E.D., Storb R. Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-ver-sus-host disease and the effect of interleukin-2. J. Immunol. 1983; 130: 712–716
   PubMed Web of Science ®Google Scholar
• Schneider L.C., Antin J.H., Weinstein H., Abrams J.S., Pearce M.K., Geha R.S., Vercelli D. Lymphokine profile in bone marrow transplant recipients. Blood 1991; 78: 3076–3080
   PubMed Web of Science ®Google Scholar
• Cayeux S., Meuer S., Pezzutto A., Korbling M., Haas R., Schulz R., Dorken B. T-cell ontogeny after autologous bone marrow transplantation: Failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4+ and CD8+ cells even in the presence of exogenous IL-2. Blood 1989; 74: 2270–2277
   PubMed Web of Science ®Google Scholar
• Ackerstein A., Kedar E., Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991; 78: 1212–1215
   PubMed Web of Science ®Google Scholar
• Johnson C.S., Thurlow S.M., Furmanski P. Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice. Leukemia 1989; 3: 91–96
   PubMed Web of Science ®Google Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Gavosto F., Mandelli F. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: A pilot study. Br. J. Haematol. 1991; 77: 491–496
   PubMed Web of Science ®Google Scholar
• Lim S.H., Newland A.C., Kelsey S., Bell A., Offerman E., Rist C., Gozzard D., Bareford D., Smith M.P., Goldstone A.H. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia-a phase II study. Cancer Immunol. Immunother. 1992; 34: 337–342
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938–948
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C.A., Herberman R.B. Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J. Immunol. 1987; 138: 2718
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C.A., Herberman R.B. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk. Res. 1987; 11: 1059–1066
   PubMed Web of Science ®Google Scholar
• Adler A., Chervenick P.A., Whiteside T.L., Lotzova E., Herberman R.B. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Hauch M., Gazzola M.V., Small T., Bordignon C., Barnett L., Cunningham I., Castro-Malaspina H., O'Reilly R.J., Keever C.A. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250–2262
   PubMed Web of Science ®Google Scholar
• Macdonald D., Jiang Y., Gordon A.A., Mahendra P., Oskam R., Palmer P.A., Franks C.R., Barrett A.J. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk. Res. 1990; 14: 967–973
   PubMed Web of Science ®Google Scholar
• Macdonald D., Jiang Y.Z., Swirsky D., Vulliamy T., Morilla R., Bungey J., Barrett A.J. Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Br. J. Haematol. 1991; 77: 43–49
   PubMed Web of Science ®Google Scholar
• Carron J.A., Cawley J.C. IL-2 and myelopoiesis: H-2 induces blast cell proliferation in some cases of acute myeloid leukaemia. Br. J. Haematol. 1989; 73: 168–172
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Rigo A., Zanotti R., Vinante F., Vincenzi C., Cassatella M., Carra G., Castaman G., Chilosi M., Semenzato G., Zambello R., Trentin L., Libonati M., Perona G. a (p55) and β (p75) chains of the interleukin-2 receptor are expressed by AML blasts. Leukemia 1993; 7: 418–425
   PubMed Web of Science ®Google Scholar
• Foa R., Caretto P., Fierro M.T., Bonferroni M., Cardona S., Guarini A., Lista P., Pegoraro L., Mandelli F., Forni G., Gavosto F. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br. J. Haematol. 1990; 75: 34–40
   PubMed Web of Science ®Google Scholar
• Makrynikola V., Kabral A., Bradstock K. Effects of interleukin 7 on the growth of clonogenic cells in T-cell acute lymphoblastic leukaemia. Leuk. Res. 1991; 15: 879–882
   PubMed Web of Science ®Google Scholar
• Bergmann L., Fenchel K., Heil G., Kolbe K., Lengfelder E., Brucher J., Lohmeyer J., Mitrou P.S., Hoelzer D. Interleukin-2 consolidation therapy in patients with 2nd remission of de novo acute myelocytic leukemia-results of a multicenter trial. Blood 1993; 82: 130a
   Web of Science ®Google Scholar
• Shepherd J.D., Jacky E., Gratwohl A., Helbig W., Maraninchi D., Zittoun R., et al. Phase II study of subcutaneous rHu interleukin-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br. J. Haematol 1994; 87(Suppl. 1)205
   PubMedGoogle Scholar
• Blaise D., Olive D., Stoppa A.M., Viens P., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., Mannoni P., Palmer P., Franks C., Philip T., Maraninchi D. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Higuchi C.M., Thompson J.A., Petersen F.B., Buckner C.D., Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561–2568
   PubMed Web of Science ®Google Scholar
• Benyunes M.C., Massumoto C., York A., Higuchi C.M., Buckner CD., Thompson J.A., Petersen F.B., Fefer A. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1993; 12: 159–163
   PubMed Web of Science ®Google Scholar
• Weisdorf D.J., Anderson P.M., Blazar B.R., Uckun F.M., Kersey J.H., Ramsay N.K.C. Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia—A phase I study. Transplantation 1993; 55: 61–66
   PubMed Web of Science ®Google Scholar
• Gottlieb D.J., Brenner M.K., Heslop H.E., et al. A phase I clinical trial of recombinant interleukin-2 following high-dose chemo-radiotherapy for haematological malignancy: Applicability to the dimination of minimal residual disease. Br. J. Cancer 1989; 60: 610–615
   PubMed Web of Science ®Google Scholar
• Hamon M.D., Prentice H.G., Gottlieb D.J., Macdonald I.D., Cunningham J.M., Smith O.P., Gilmore M., Gandhi L., Collis C. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant. 1993; 11: 399–401
   PubMed Web of Science ®Google Scholar
• Klingemann H-G., Eaves C.J., Bamett M.J., Eaves A.C., Hogge D.E., Nantel S.H., Reece D.E., Shepherd J.D., Sutherland H.J., Phillips G.L. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administra tion. Bone Marrow Transplant., (in press). (in press)
   Google Scholar
• Meloni G., Foa R., Tosti S., Vignetti M., Mancini F., Guarini A., Marchis D., Gavosto F., Mandelli F. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: A pilot study. Leukemia 1992; 6: 780–785
   PubMed Web of Science ®Google Scholar
• Baruchel A., Michel G., Bemaudin F., Lemerle S., Leblanc T., Bordigoni P., Vilmer E., et al. Interleukin-2 (IL-2) after autologous bone marrow transplantation (ABMT) in children with leukemia. Proc. Am. Assoc. Cancer Res. 1993; 34: 464
   Google Scholar
• Smith K.A. Lowest dose interleukin-2 immunotherapy. Blood. 1993; 81: 1414–1423
   PubMed Web of Science ®Google Scholar
• Toze C.L., Barnett M.J., Klingemann H-G. Response of therapy-related myelodysplasia to low-dose interleukin-2. Leukemia 1993; 7: 463–465
   PubMed Web of Science ®Google Scholar
• Soiffer R.J., Murray C., Cochran K., Cameron C., Wang E., Schow P.W., Daley J.F., Ritz J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517–526
   PubMed Web of Science ®Google Scholar
• Caligiuri M.A., Murray C., Robertson M.J., Wang E., Cochran K., Cameron C., Schow P., et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 1993; 91: 123–132
   PubMed Web of Science ®Google Scholar
• Foa R., Guarini A., Gillio Tos A., Cardona S., Fierro M.T., Meloni G., Tosti S., Mandelli F., Gavosto F. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: Evidence of in vivo lymphokine activated killer cell generation. Cancer Res. 1991; 51: 964–968
   PubMed Web of Science ®Google Scholar
• Gottlieb D.J., Prentice H.G., Heslop H.E., Bello-Femandez C., Bianchi A.C., Galazka A.R., Brenner M.K. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 1989; 74: 2335–2342
   PubMed Web of Science ®Google Scholar
• Soiffer R.J., Canning C., Gonin R., Ritz J. Influence of low dose interleukin-2 on relapse rate after T-cell depleted allogeneic BMT. Blood 1993; 82: 215a, Suppl. 1
   Web of Science ®Google Scholar
• Klingemann H-G., Grigg A.P., Wilkie-Boyd K., Barnett M.J., Eaves A.C., Reece D.E., Shepherd J.D., Phillips G.L. Treatment with recombinant interferon (a-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1991; 78: 3306–3311
   PubMed Web of Science ®Google Scholar
• Vivancos P., Granena A., Garcia J., Abad B., Vails A. Post-ABMT treatment with high doses of IL2 and IFN. Results of a phase II study (abstract). Proceedings of the 19th Annual Meeting of the EBMT and 9th Meeting of the Nurses Group, Garmisch-PartenkirchenGermany, January, 17–211993, 123
   Google Scholar
• Long G.S., Hiserodt J.C., Harnaha J.B., Cramer D.V. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Transplantation 1988; 46: 433–438
   PubMed Web of Science ®Google Scholar
• Long G.S., Cramer D.V., Hamaha J.B., Hiserodt J.C. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: Range of activity against different hematopoietic neoplasms. Bone Marrow Transplant. 1990; 6: 169–177
   PubMed Web of Science ®Google Scholar
• Charak B.S., Brynes R.K., Groshen S., Chen S-C., Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990; 76: 2187–2190
   PubMed Web of Science ®Google Scholar
• Klingemann H-G., Deal H., Reid D., Eaves C.J. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp. Hematol. 1993; 21: 1263–1270
   PubMed Web of Science ®Google Scholar
• van den Brink M.R.M., Voogt P.J., Marjit W.A.F., van Luxemburg-Heys S.A.P., ban Rood J.J., Brand A. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 1989; 74: 354–360
   PubMed Web of Science ®Google Scholar
• Bellone G., Fierro M.T., Liao X-S., Tos A.G., Bonferroni M., Pegoraro L., Foa R. Lymphokine activated killer (LAK) cells inhibit the in vitro growth of myeloid and erythroid progenitor cells via the release of tumor necrosis factor-alpha. Leuk Lymphoma 1990; 1: 341–352
   PubMedGoogle Scholar
• Murphy W.J., Keller J.R., Harrison C.L., Young H.A., Longo D.L. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 1992; 80: 670
   PubMed Web of Science ®Google Scholar
• Pendry K., Alcorn M.J., Burnett A.K. Factors influencing haematological recovery in 53 patients with acute myeloid leukaemia in first remission after autologous bone marrow transplantation. Br. J. Haematol. 1993; 83: 45–52
   PubMed Web of Science ®Google Scholar
• Gong J-H., Thacker J.D., Klingemann H-G. Use of IL-2 activated bone marrow to eliminate minimal residual acute myeloid leukemia prior to autologous marrow transplantation. Exp. Hematol. 1992; 20: 728
   Web of Science ®Google Scholar
• Klingemann H-G., Neerunjun J., Schwulera H., Ziltener H. Culture of normal and leukemic bone marrow in interleukin-2: Analysis of cell activation, cell proliferation, and cytokine production. Leukemia 1993; 7: 1389–1393
   PubMed Web of Science ®Google Scholar
• Coulombel L., Eaves C., Kalousek D., Gupta C., Eaves A. Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases. /. Clin. Invest. 1985; 75: 961–969
   Google Scholar
• Kühr T., Dougherty G., Klingemann H.-G. Transfer of the TNF-a gene into hematopoietic progenitor cells as a model for site-specific cytokine delivery after marrow transplantation. Blood 1994, (in press)
   PubMedGoogle Scholar
• Pavletic Z., Benyunes M.C., Thompson J.A., Lindgren C.G., Massumoto C., Alderson M.R., Buckner C.D., Fefer A. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy. Exp. Hematol 1993; 21: 1371–1378
   PubMed Web of Science ®Google Scholar
• Soiffer R.J., Robertson M.J., Murray C., Cochran K., Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993; 82: 2790–2796
   PubMed Web of Science ®Google Scholar